{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dermatologic+Disorders&page=23",
    "query": {
      "condition": "Dermatologic Disorders",
      "page": 23
    },
    "page_size": 10
  },
  "pagination": {
    "page": 23,
    "page_size": 10,
    "total_count": 13600,
    "total_pages": 1360,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dermatologic+Disorders&page=24&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dermatologic+Disorders&page=22&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-27T04:42:35.859Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04639245",
      "title": "Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Metastatic Lung Non-Small Cell Carcinoma",
        "Metastatic Malignant Solid Neoplasm",
        "Metastatic Triple-Negative Breast Carcinoma",
        "Metastatic Urothelial Carcinoma",
        "Stage IV Lung Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PD1 Inhibitor",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2021-07-19",
      "completion_date": "2022-08-16",
      "has_results": true,
      "last_update_posted_date": "2023-08-03",
      "last_synced_at": "2026-10-27T04:42:35.859Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04639245"
    },
    {
      "nct_id": "NCT02623972",
      "title": "A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Inflammatory Breast Cancer",
        "Human Epidermal Growth Factor 2 Negative Carcinoma of Breast"
      ],
      "interventions": [
        {
          "name": "Eribulin",
          "type": "DRUG"
        },
        {
          "name": "Adriamycin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2016-02-26",
      "completion_date": "2026-12",
      "has_results": true,
      "last_update_posted_date": "2026-07-06",
      "last_synced_at": "2026-10-27T04:42:35.859Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02623972"
    },
    {
      "nct_id": "NCT04074512",
      "title": "Copper Histidinate Treatment for Menkes Disease",
      "overall_status": "APPROVED_FOR_MARKETING",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Menkes Disease"
      ],
      "interventions": [
        {
          "name": "copper histidinate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sentynl Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "6 Years",
        "sex": "ALL",
        "summary": "0 Years to 6 Years"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2026-03-02",
      "last_synced_at": "2026-10-27T04:42:35.859Z",
      "location_count": 20,
      "location_summary": "Phoenix, Arizona • Sacramento, California • San Diego, California + 17 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04074512"
    },
    {
      "nct_id": "NCT05583019",
      "title": "Atopic Dermatitis With Accelerometry and Polysomnography (ADAP)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Atopic Dermatitis",
        "Eczema",
        "Healthy"
      ],
      "interventions": [
        {
          "name": "GENEActiv Accelerometry Device",
          "type": "DEVICE"
        },
        {
          "name": "Centrepoint Insights Watch (CPIW) Accelerometry Device",
          "type": "DEVICE"
        },
        {
          "name": "Apple Watch Accelerometry Device",
          "type": "DEVICE"
        },
        {
          "name": "Polysomnography",
          "type": "DEVICE"
        },
        {
          "name": "Videography",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "SymmetryScience Group, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "12 Years to 75 Years"
      },
      "enrollment_count": 88,
      "start_date": "2022-10-27",
      "completion_date": "2023-05-11",
      "has_results": false,
      "last_update_posted_date": "2023-08-15",
      "last_synced_at": "2026-10-27T04:42:35.859Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05583019"
    },
    {
      "nct_id": "NCT04817228",
      "title": "A Study to Evaluate the Clinical Performance, Safety and Pharmacology Effect of EscharEx in Patients With Lower Leg Ulcers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Venous Leg Ulcer",
        "Diabetic Foot Ulcer"
      ],
      "interventions": [
        {
          "name": "EscharEx (EX-02 formulation)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MediWound Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 12,
      "start_date": "2021-04-21",
      "completion_date": "2022-05-20",
      "has_results": false,
      "last_update_posted_date": "2022-07-26",
      "last_synced_at": "2026-10-27T04:42:35.859Z",
      "location_count": 3,
      "location_summary": "Tamarac, Florida • Las Vegas, Nevada • Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Tamarac",
          "state": "Florida"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04817228"
    },
    {
      "nct_id": "NCT00257465",
      "title": "Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Autologous, DNP-modified vaccine (M-Vax)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Autologous, DNP-Modified Melanoma Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Autologous, DNP-Modified Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AVAX Technologies",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 82,
      "start_date": "2005-06",
      "completion_date": "2008-06",
      "has_results": false,
      "last_update_posted_date": "2015-12-03",
      "last_synced_at": "2026-10-27T04:42:35.859Z",
      "location_count": 7,
      "location_summary": "Tucson, Arizona • San Diego, California • Chicago, Illinois + 3 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00257465"
    },
    {
      "nct_id": "NCT04752267",
      "title": "18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Glioma",
        "Malignant Brain Neoplasm",
        "Metastatic Breast Carcinoma",
        "Metastatic Colon Carcinoma",
        "Metastatic Kidney Carcinoma",
        "Metastatic Lung Carcinoma",
        "Metastatic Malignant Neoplasm in the Brain",
        "Metastatic Melanoma",
        "Pathologic Stage IV Cutaneous Melanoma AJCC v8",
        "Prognostic Stage IV Breast Cancer AJCC v8",
        "Stage IV Colon Cancer AJCC v8",
        "Stage IV Lung Cancer AJCC v8",
        "Stage IV Renal Cell Cancer AJCC v8",
        "Stage IVA Colon Cancer AJCC v8",
        "Stage IVA Lung Cancer AJCC v8",
        "Stage IVB Colon Cancer AJCC v8",
        "Stage IVB Lung Cancer AJCC v8",
        "Stage IVC Colon Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "18F-FMAU",
          "type": "DRUG"
        },
        {
          "name": "Multiparametric Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2021-02-15",
      "completion_date": "2023-09-18",
      "has_results": false,
      "last_update_posted_date": "2024-05-24",
      "last_synced_at": "2026-10-27T04:42:35.859Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04752267"
    },
    {
      "nct_id": "NCT06072807",
      "title": "Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Breast Cancer",
        "Brain Metastases"
      ],
      "interventions": [
        {
          "name": "Brain Imaging with 18F-FES",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 20,
      "start_date": "2023-12-27",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2025-11-24",
      "last_synced_at": "2026-10-27T04:42:35.859Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06072807"
    },
    {
      "nct_id": "NCT02975271",
      "title": "Study of the Efficacy, Safety & Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pruritus",
        "Burns"
      ],
      "interventions": [
        {
          "name": "Serlopitant",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vyne Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 1,
      "start_date": "2016-11",
      "completion_date": "2017-01-17",
      "has_results": false,
      "last_update_posted_date": "2021-05-20",
      "last_synced_at": "2026-10-27T04:42:35.859Z",
      "location_count": 7,
      "location_summary": "Phoenix, Arizona • Washington D.C., District of Columbia • Gainesville, Florida + 4 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02975271"
    },
    {
      "nct_id": "NCT03569371",
      "title": "A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hidradenitis Suppurativa"
      ],
      "interventions": [
        {
          "name": "INCB054707",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 10,
      "start_date": "2018-07-17",
      "completion_date": "2019-04-22",
      "has_results": true,
      "last_update_posted_date": "2022-09-26",
      "last_synced_at": "2026-10-27T04:42:35.859Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Tampa, Florida • New York, New York + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03569371"
    }
  ]
}